Overview

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

Status:
Completed

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

The most prevalent monogenetic diabetic subtype is named maturity onset diabetes of the young type (MODY3) or hepatocyte nuclear factor 1α (HNF1A)-diabetes. The aim of this study is to evaluate the effects of supra-physiological levels of GIP and GLP-1, respectively, on insulin and glucagon secretion at fasting plasma glucose (FPG) and "post-prandial" PG levels (1.5 × FPG) in patients with HNF1A-diabetes and matched healthy controls treated with or without a low dose of glimepiride (sulphonylurea). In addition, we will evaluate the maximal insulin and glucagon secretory capacity in both groups.

Phase:

N/A

Details

Lead Sponsor:

University Hospital, Gentofte, Copenhagen

Treatments:

Gastric Inhibitory Polypeptide
Glimepiride
Glucagon
Glucagon-Like Peptide 1